

# impedimed

20 July 2018

## ASX ANNOUNCEMENT

### ImpediMed Quarterly Results and Investor Conference Call

**Brisbane, Australia** - ImpediMed Limited (ASX: IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 30 June 2018, on Monday 23<sup>rd</sup> July 2018.

Investors are invited to join a conference call with Managing Director and CEO, Richard Carreon at **9.00am AEST on Monday 23<sup>rd</sup> July 2018**.

To pre-register please follow this link:

<https://services.choruscall.com.au/diamondpass/ImpediMed-272656-Invite.html>

*You will receive a calendar notification with dial in details and a PIN for fast track access to the call.*

#### Media and Investor Contacts:

##### In Australia:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: [kwilliamson@we-buchan.com](mailto:kwilliamson@we-buchan.com)

#### About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

For personal use only